Randomized controlled clinical trials (RCT’s) have shown that inhibiting VEGF production by using intravitreal anti-VEGF agents is also effective, but not entirely so, particularly for macular edema [reviewed in (212–214)], indicating that there are other factors at play in the tissue fluid accumulation. The gene discussed is VEGFA; the disease is macular retinal edema.